SCHEMBL941589

SCHEMBL941589

COc1cccc2c(C(C[PH](=O)O)C(=O)Nc3ccc4ccccc4c3)coc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 3/20 0.45
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
CASP3 P42574 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
NQO2 P16083 1/20 0.40
ROCK2 O75116 1/20 0.40
MAPT P10636 3/20 0.39
PSMB8 P28062 1/20 0.38
PSMB5 P28074 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
PPARG P37231 1/20 0.38
NR2E3 Q9Y5X4 1/20 0.38
NCOR2 Q9Y618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942502 0.83 CMA1 (0.63) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL942970 0.83 CMA1 (0.50) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL941582 0.83 CMA1 (0.50) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL943094 0.82 CMA1 (0.40) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL942773 0.81 CMA1 (0.69) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL941590 0.80 CMA1 (0.64) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL943753 0.80 CMA1 (0.44) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL942383 0.79 CMA1 (0.42) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL944661 0.77 CMA1 (0.53) CMA1NPC1RAB9AMEN1KMT2A
SCHEMBL942532 0.77 CMA1 (0.52) CMA1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872044-B2 (thio)amide benzofuran compounds containing phosphonic, phosphinic, sulfonic, sulfamic, or carboxy acid groups; for example [benzofuran-3-yl-(naphthalen-2-ylcarbamoyl)-methyl]-phosphonic acid; treating inflammatory or serine protease mediated disorders such as allergic rhinitis, asthma and heart failure JANSSEN PHARMACEUTICA NV (BE) 2011-01-18 US claimed
EP-2097399-A2 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-09 EP claimed
US-20080096844-A1 Novel inhibitors of chymase JANSSEN PHARMACEUTICA, N.V. (BE) 2008-04-24 US claimed
WO-2008048668-A2 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA, N.V. (BE) 2008-04-24 WO claimed
EP-2097399-A2 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-09 EP disclosed
US-20080096844-A1 Novel inhibitors of chymase JANSSEN PHARMACEUTICA, N.V. (BE) 2008-04-24 US disclosed
WO-2008048668-A2 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA, N.V. (BE) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096844-A1 Novel inhibitors of chymase CMA1, SERPINB1, PRSS1 CMA1 1/4885NPC1 407/4885RAB9A 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.